Box 1Treatment regimens

• No treatment
• Paracetamol 3000 mgDose based on Average Daily Quantity (ADQ) as stated by the Prescribing Support Unit (see Box 2).
• Diclofenac 100 mgStandard NSAIDs, considered at the ADQ doses. Higher doses that are licensed and commonly used are also considered in sensitivity analyses.
• Naproxen 750 mg
• Ibuprofen 1200 mg
• Diclofenac 100 mg + PPIStandard NSAIDs at the ADQ doses, with the addition of concurrent PPI (20 mg omeprazole per day). Higher doses of standard NSAIDs that are licensed and commonly used are also considered in sensitivity analysis
• Naproxen 750 mg + PPI
• Ibuprofen 1200 mg + PPI
• Celecoxib 200 mgCOX-2 inhibitors, considered at the ADQ doses. Etoricoxib is also available at a lower dose of 30 mg, and this is tested in a sensitivity analysis.
• Etoricoxib 60 mg
• Celecoxib 200 mg + PPICOX-2 inhibitors, considered at the ADQ, with the addition of concurrent GPA (20 mg omeprazole per day.
• Etoricoxib 60 mg + PPI

From: Appendix D, Details of the NSAID/COX-2 inhibitor health economic model

Cover of Osteoarthritis
Osteoarthritis: National Clinical Guideline for Care and Management in Adults.
NICE Clinical Guidelines, No. 59.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.